C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A system for authenticating an object includes at least one laser configured for interacting with a tag, the tag comprising structural changes to the object, the structural changes being responsive to terahertz electromagnetic waves. The system may also include a processor configured to (i) receive electromagnetic wave data resulting from interaction of the terahertz electromagnetic waves with the structural changes, (ii) compare the electromagnetic wave data to a reference standard, (iii) determine that the object is authentic in response to the electromagnetic wave data meeting the reference standard, and (iv) determine that the object is not authentic in response to the electromagnetic wave data not meeting the reference standard. A system for reading a tag of an object is further provided.
G06K 7/10 - Methods or arrangements for sensing record carriers by electromagnetic radiation, e.g. optical sensingMethods or arrangements for sensing record carriers by corpuscular radiation
5.
SYSTEMS AND METHODS FOR NUCLEIC ACID EXTRACTION AND VISUAL DETECTION
Disclosed are methods, devices and kits for extracting, amplifying, detecting and visualizing nucleic acids of interest for use in onsite rapid diagnostics.
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
The Board of Regents of the University of Oklahoma (USA)
The Board of Trustees of The Leland Stanford Junior University (USA)
The University of Connecticut (USA)
Inventor
Shabgard, Hamidreza
Faghri, Amir
Goodson, Kenneth
Asheghi, Mehdi
Abstract
A connector apparatus for an electric charging cable, such as for use with a charging station and an electric vehicle, the connector apparatus comprising: a connector block having a first end and a second end, the first end having one or more connectors configured to pass electrical energy through an electric cable; the electric cable having an end portion that is fixed within the connector block, the electric cable extending out of the connector block from the second end of the connector block and configured to transfer electric current; and a plurality of heat pipes having fixed ends fixed within the connector block and having exposed ends extending out of the second end of the connector block, the plurality of heat pipes configured to dissipate heat from the connector block through the exposed ends of the plurality of heat pipes.
F28D 15/04 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes with tubes having a capillary structure
F28D 21/00 - Heat-exchange apparatus not covered by any of the groups
The present disclosure describes compositions and methods including liposome or lipid nanoparticles (LNPs) including carbohydrate-based ligands that target the liver, lungs, and/or kidneys. More particularly, the present disclosure relates to compositions and methods including liposome or lipid nanoparticles (LNPs) including carbohydrate-based ligands, such as di-lactobionic acid (LBA) ligand, and a suitable cargo such as nucleic acids and small molecule to target the liver, lungs, and/or kidneys for treatment and/or diagnosis of diseases and conditions.
A system and method for generating a three-dimensional image of a sample. The system comprises a platform configured to support the sample, a laser source configured to output a laser beam to remove material from the sample, a microscope imaging system, and a controller communicatively coupled to the laser source and the microscope imaging system. The controller is configured to (a) acquire height data of a surface of the sample with the microscope imaging system, (b) generate a mask based on the height data of the surface of the sample, the mask providing a laser cutting pattern for the sample, (c) acquire an image and a height map of the surface of the sample with the microscope imaging system, (d) activate the laser source to generate a laser beam to delayer the sample based on the mask, and repeat steps (a)-(d) to generate a three-dimensional image of the sample.
A method for improving intelligibility of speech and/or warning sounds generated in a noisy environment including receiving an audio signal from the noisy environment, segmenting the audio signal into a plurality of frequency bandwidths to provide a plurality of temporal bandwidth limited signals, and providing each temporal bandwidth limited signal to an associated signal path and an associated control path in parallel with the associated signal path. The method also includes filtering the temporal envelope bandwidth signal in each associated control path using a delayless filter to provide an associated control signal, modulating an amplitude of the temporal bandpass signal in each associated signal path using the associated control signal to provide an associated output signal, and combining the associated output signals to provide a combined output signal that improves the intelligibility of the speech and/or warning sounds generated in the noisy environment.
Disclosed herein are methods for prognosing the risk of progression of a disease or disorder associated with inflammation, e.g., asthma, in a subject. Such methods include detecting levels of a fungal species comprising Malassezia globosa in the subject.
C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
A method of making a biodegradable piezoelectric composite material is provided. Such a method may include mixing a solution comprising biodegradable polymer, glycine crystal, and at least one solvent. The method further comprises electrospinning the solution and receiving the electrospun solution onto a collector drum having a speed of about 100 RPM to about 4,000 RPM. The resulting biodegradable polymer fibers are then substantially aligned with each other. Also provided is a composite material having glycine crystal and a biodegradable polymer.
The present disclosure provides compositions, systems, pre-filled delivery devices, and methods for developing injectable compositions useful for in situ forming solid depots for the sustained release of non-steroidal anti-inflammatory drug NSAIDs over a period of days to several months for use in treating or preventing inflammation. The compositions comprise a biodegradable polymer such as poly(lactic-co-glycolic acid) (PLGA), a solvent such as N-Methyl-2-pyrrolidone, and a NSAID such as naproxen, meloxicam. The compositions may optionally comprise an additive such as hydrogenated soy L-α-phosphatidylcholine (HSPC) or a second active agent. The depot material will be robust to exist within the desired site for a period similar to or greater than the planned period of drug delivery.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
13.
Biomimetic hybrid nanocoating composition, methods of use thereof and coatings produced therefrom
An article includes a substrate and a coating disposed on the substrate. The coating includes a binder and a plurality of nanosheets. The plurality of nanosheets are arranged in layers and are oriented with their largest surfaces being substantially parallel to a surface of the substrate upon which they are disposed.
Antibodies against the immune checkpoint molecules Erythroid membrane-associated protein (ERMAP/BTN5), TAP Binding Protein Like protein (TAPBPL), and CD300c are provided, and their use for treating cancer.
An apparatus for treating an abnormality includes a processor and a non-transitory computer readable medium that includes a first convolutional neural network (CNN) having weights and a second CNN in parallel with the first CNN and sharing the weights, the second CNN being joined to the first neural network by a distance function. The medium includes instructions that when executed by the processor implements a method. The method includes receiving a first image dataset of an area of interest and processing the first image dataset using the first CNN and receiving a second image dataset of the area of interest obtained prior to the first image dataset and processing the second image dataset using the second CNN. The method also includes identifying the abnormality using an output of the distance function wherein the identifying influences treatment of the abnormality.
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
The present disclosure describes a multi-layered multifunctional liposomal metal organic framework (MOF) nucleic acid nanocapsule capable of stabilizing therapeutic nucleic acid cargo, particularly mRNA. More particularly, the present disclosure relates to a multifunctional nanoparticle that functions as a nucleic acid delivery material which can both deliver and release mRNA to cells in an enzyme specific fashion; and methods of using such nanoparticles for treatment and/or diagnosis of diseases and conditions.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
The present invention provides cationic polymeric nanoparticles, and nanoparticle formulations thereof. The invention also provides methods for preparing cationic polymeric nanoparticles, and methods of treating diseases, reducing tumor growth, and increasing uptake of a therapeutic agent by a tumor cell in a subject in need thereof.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
Disclosed herein are methods for restoring, repairing, or regenerating cartilage in a subject in need of treatment thereof by including at least one natural growth factor in a composition that is injected or implanted into a subject.
Materials, methods, and techniques herein relate to stents. More specifically, the instant disclosure relates to stents, such as catheters, for slow-release drug delivery of urological therapeutic agents.
12166 alkyl, X1is selected from the group consisting of O, NR3, C=O, and C(R32 2 where R33166 alkyl, X2is O, NR3, or C(R322 where R3166 alkyl; n1is 1 to 20, G1and G4are each a direct bond or a chemical linker; and G4-CL is a carbohydrate ligand structure comprising 2 to 16 carbohydrate residues each derived from a monosaccharide, a disaccharide, a trisaccharide, or a tetrasaccharide; where cc is 2 to 16.
An implantable scaffold is provided including multiple piezoelectric films and at least one compressible intervening layer. A first of the piezoelectric films is on a first side of the compressible intervening layer and a second of the plurality of piezoelectric films is on a second side of the compressible intervening layer opposite the first piezoelectric film. Upon applying a mechanical force to the first piezoelectric film, the first piezoelectric film deforms towards the second piezoelectric film. Also provided is a method of treatment leveraging the implantable scaffold.
A61N 1/32 - Applying electric currents by contact electrodes alternating or intermittent currents
A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
H10N 30/078 - Forming of piezoelectric or electrostrictive parts or bodies on an electrical element or another base by depositing piezoelectric or electrostrictive layers, e.g. aerosol or screen printing by liquid phase deposition by sol-gel deposition
H10N 30/50 - Piezoelectric or electrostrictive devices having a stacked or multilayer structure
22.
Sample Collection Card for Untargeted Metabolomics and Methods of Use Thereof
A liquid sample collection system is provided. The system includes a housing having a first layer and a second layer coupled to the first layer, one or more channels integrated into the first layer from a central region of the first layer to an edge of the first layer, and a card secured between the first layer and the second layer. The first layer is made, at least in part, from a hydrophobic polymer and the second layer is made, at least in part, from a hydrophilic polymer, and the one or more channels distribute the liquid sample on the card.
The present disclosure relates to compositions and methods for growing a cell line which can be used to generate bovine pluripotent embryonic stem cells. The composition comprises a cell culture medium and at least one supplement, wherein the composition maintains pluripotency and self-renewal capacity of the cell/s. The methods employ the compositions to produce bovine embryonic stem cells which maintain their pluripotency and self-renewing capacity
C12N 1/38 - Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factorsStimulation of growth by removal of a chemical compound
C12N 15/873 - Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
24.
Autonomous Optimization of Inkjet Printing Through Machine Learning
Active machine learning with model selection is used to control a printing system to efficiently, accurately, and autonomously predict jettability diagrams for different print head and ink combinations. A print system may be controlled using active machine learning to efficiently and accurately predict a jetting behavior for different combinations of ink and inkjet print heads at different settings/values for operating parameters of the print heads, such as firing voltage, pulse width/dwell time, frequency, ramp up, ramp down, meniscus pressure, heating rate, hold time, transducers' positions, geometries, and heating power, and/or other operating parameters of the print heads.
Disclosed herein is an adapter for use in facilitating dissolution, the adapter comprising a container body and a cavity that is operative to contain a suspension disposed in the container body; where the cavity comprises a conical section that protrudes into the container body; or where the cavity comprises a partial ellipsoidal shape that protrudes into the container body.
An apparatus for performing an activity based on a sympathetic nervous system (SNS) response to a stimulus includes an electrode configured to contact a person undergoing the stimulus. The apparatus also includes a processing unit having an algorithm programmed by machine-learning and configured to: (i) receive at least one of electrocardiogram (ECG) signals or electrodermal activity (EDA) signals from the electrode; (ii) analyze at least one of skin sympathetic nerve activity (SKNA) signals derived from the ECG signals or the EDA signals to measure the SNS response and provide an SNS response measurement; and (iii) transmit an SNS response measurement signal conveying the SNS response measurement to initiate the activity. The apparatus also includes an activity device configured to perform the activity in response to the SNS response measurement signal.
Disclosed herein is a device for detecting nucleic acids, the device comprising a CRISPR-Cas13a-mediated graphene field-effect transistor comprising a source electrode; a drain electrode; a gate electrode; a detection channel; where the channel comprises a CRISPR-Cas13a-mediated graphene layer; where Cas13a is operative to function as an effector protein that targets a specific RNA sequence for cleavage based on a recognition of the RNA sequence by crRNA. Disclosed herein too is a device for detecting nucleic acids, the device comprising a CRISPR-Cas12a-mediated graphene field-effect transistor comprising a source electrode;
a drain electrode; a gate electrode; a detection channel; where the channel comprises a CRISPR-Cas12a-mediated graphene layer; where Cas12a is operative to function as an effector protein that targets a specific DNA sequence for cleavage based on a recognition of the DNA sequence by crRNA.
Disclosed herein is a nasogastric device comprising a multi-lumen tubular conduit having a proximal end and a distal end with a plurality of conduits arranged therebetween; a plurality of inlet ports located at the proximal end in fluid communication with the plurality of conduits; where the plurality of conduits are arranged such that at least one conduit of the plurality of conduits is located with a wall of another conduit; where at least one conduit of the plurality of conduits is in fluid communication with an inflatable balloon; and where at least one conduit of the plurality of conduits is in fluid communication with a drug delivery inlet port.
Disclosed are fibronectin-based peptides, and novel nucleic acids and compositions comprising the same, for promoting neuroprotection and/or axon regeneration in neurons. Disclosed herein are methods to treat or prevent neuronal injury and disease and disorders characterized by neuronal injury.
The present disclosure provides methods for making decellularized skeletal muscle extracellular matrix (smECM) hydrogels, as well as compositions and methods of treatment related to the smECM hydrogels.
A test system (20) has: a base (30); first and second support posts (40A, 40B) extending upward from the base; and a crosshead (44) receiving the first and second support posts. The crosshead is movable along a vertical range of motion relative to the first and second support posts and lockable to the first and second support posts within that range of motion. An actuator (70) provides a vertical force between the base and the locked crosshead. The vertical force is converted to a horizontal force on a specimen (26).
The present invention provides cationic polymeric nanoparticles, and nanoparticle formulations thereof. The invention also provides methods for preparing cationic polymeric nanoparticles, and methods of treating diseases, reducing tumor growth, and increasing uptake of a therapeutic agent by a tumor cell in a subject in need thereof.
A thin-film composite membrane may comprise a mixed-matrix membrane supported by a substrate, the mixed-matrix membrane comprising two or more sublayers. At least one of the sublayers may comprise 10 by weight (wt %) to 75 wt % filler particles and 25 wt % to 90 wt % polymer. A method of making a thin-film composite membrane may include performing an electrospraying cycle, comprising electrospraying a first solution onto a surface of a substrate, the solution comprising a first solvent and filler particles, the substrate being positioned on a support surface; electrospraying a second solution onto the surface of the substrate, the second solution comprising a second solvent and a polymer; and after electrospraying a predetermined number of cycles, removing the substrate from the support surface.
B01D 53/22 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
Disclosed herein is a scaffold for use in a body of a living being, the scaffold comprising a biodegradable portion; and a non-degradable portion; where the biodegradable portion form the major portion of the scaffold; and where the biodegradable portion and the non-degradable portion both comprise biocompalible polymers. Disclosed herein too is a method of manufacturing a scaffold for tissue regeneration, the method comprising braiding a first fiber with a second fiber to form a braid; where the first fiber comprises a biodegradable polymer and where the second fiber comprises a non-degradable polymer; where the first fiber is present in an amount of greater than 50 wt%, based on a total weight of the scaffold.
36.
CARDIOPULMONARY RESUSCITATION, TREATMENT, AND ANALYSIS
An apparatus for treating a person having cardiac arrest includes a processor and a lead in communication with the processor, the lead being configured to receive a segment of electrocardiogram (ECG) data from the person while undergoing cardiopulmonary resuscitation (CPR). The apparatus also includes a non-transitory computer-readable medium having: a first Convolutional Neural Network-based Encoder-Decoder (CNNED) structure to reduce artifacts due to the CPR; a second CNNED structure cascaded with the first CNNED structure to further reduce artifacts; and instructions to determine a first arrhythmia classification using the first CNNED structure, determine a second arrhythmia classification using the second CNNED structure in response to the first arrhythmia classification indicating a shockable arrhythmia event; and transmit a signal to apply a defibrillation shock to the person in response to the first arrhythmia classification and the second arrhythmia classification indicating a shockable arrhythmia of the person.
Disclosed herein is an analgesic composition comprising a nanoparticle and/or a microparticle that comprises a charged lipid and/or a supporting lipid; where the charged lipid comprises an electrically charged group. Disclosed herein too is a method of reducing joint inflammation, swelling and/or pain in a subject, the method comprising administering a therapeutically effective amount an analgesic composition to the subject; where the analgesic composition comprises a nanoparticle and/or a microparticle that comprises a charged lipid and/or a supporting lipid; where the charged lipid comprises an electrically charged group.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
38.
INHIBITORS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS
Described herein are compounds of Formula I, wherein the meanings of the substituents are indicated in the description, for modulating a reproductive and respiratory syndrome virus through multiple mechanisms, and to their use as medicaments for the prevention and/or treatment of diseases related to a reproductive and respiratory syndrome virus. Pharmaceutical compositions comprising said compounds of Formula I are also described.
A recyclable composition includes a proteinaceous biopolymer. The proteinaceous biopolymer forms a matrix of the recyclable composition and encapsulates a recyclable polymer. The recyclable polymer is dispersed in the proteinaceous biopolymer. A method of manufacturing a recyclable composition includes blending a proteinaceous biopolymer with a recyclable polymer to form the recyclable composition. The proteinaceous biopolymer forms a matrix of the recyclable composition and the recyclable polymer is dispersed in the proteinaceous biopolymer.
C08J 11/04 - Recovery or working-up of waste materials of polymers
C08J 11/02 - Recovery or working-up of waste materials of solvents, plasticisers or unreacted monomers
C08J 11/10 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation
40.
RECYCLEABLE BIOPLASTICS, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME
A crosslinkable composition includes a proteinaceous biopolymer; a crosslinking agent; and a plasticizer. A crosslinked composition includes a crosslinked proteinaceous biopolymer that includes bovine serum albumin, papain, whey, zein, or a combination thereof. A method of manufacturing a crosslinked composition includes blending a proteinaceous biopolymer with a crosslinking agent to form a crosslinkable composition. The crosslinkable composition is then molded and heated to form the crosslinked composition.
Disclosed herein are polycannabinoids and polycannabinoid compositions which find use as a commodity polymer and for commodity electronics. Suitable uses include coatings and paints. Polycannabinoids can be used as polymer dielectrics for capacitors and capacitive energy storage. Also disclosed are new electrochromic materials comprising polycannabinoids and a salt. Further disclosed are electrochromic devices prepared from the electrochromic materials and electrochromic material compositions.
C09D 123/02 - Coating compositions based on homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bondCoating compositions based on derivatives of such polymers not modified by chemical after-treatment
C09D 167/02 - Polyesters derived from dicarboxylic acids and dihydroxy compounds
G02F 1/1516 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect characterised by the electrochromic material, e.g. by the electrodeposited material comprising organic material
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Methods for enhancing myogenic and/or chondrogenic lineage commitment of stem cells, inhibiting adipogenic differentiation of stem cells, and for promoting tissue regeneration using fibroblast growth factor 8 (FGF8).
The present invention relates to compounds able to modulate the protein GLI1 having the formula wherein the meanings of the substituents are indicated in the description, for use in the prevention and/or treatment of diseases related to GLI1. The present invention also relates to compounds of Formula I, Ia, Tb, Ic, Id, Ie, and Ie1 for modulating GLI1-mediated transcription through multiple mechanisms, and to their use as medicaments, in particular for the prevention and/or treatment of diseases related to GLI1, more in particular for the treatment of tumors. Pharmaceutical compositions comprising said compounds of Formula I, Ia, Tb, Ic, Id, Ie, or Ie1 are also within the scope of the present invention.
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
46.
REAGENTS AND METHODS FOR TREATING CANCER AND AUTOIMMUNE DISEASE
Disclosed herein are methods for treating cancer by administering to a subject having cancer antibodies against one or more of CD300c, BTN5 (Erythroid membrane-associated protein), TAPBPL (antigen processing (TAP) binding protein like protein), Skint8 (selection and upkeep of intraepithelial T cells 8 protein), and CD300f. Also disclosed herein are methods for treating autoimmune diseases by administering to a subject having an autoimmune disease an IgV domain, or a nucleic acid encoding an IgV domain, from one or more of CD300c, BTN5, TAPBPL, Skint8, and CD300f. Also disclosed herein are antibodies against CD300c and TAPBPL, and fusion proteins that can be used in the methods for treating autoimmune disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The disclosure provides methods and compositions for All-In-One Dual CRISPR-Cas12a (termed “AIOD-CRISPR”) permit simple, rapid, ultrasensitive, specific, one-pot and visual detection of nucleic acids (DNA and RNA).
Systems and methods for synthesis of ammonia are provided. Ammonia is synthesized using a bi-functional material in a chemical looping reactor, in two steps. The first step involves fixing nitrogen to the surface of the bi-functional material. In a second step, hydrogen is introduced to the surface of the material to react with the lattice nitrogen, generating ammonia. The order of these steps can be reversed. The system may include a control system in communication with the reactor to control operational parameter(s) associated with operation of the reactor for production of ammonia. The operational parameter(s) may include temperature, pressure, residence time, concentration and/or humidity. Ammonia may be supplied various downstream applications or processes, e.g., a fuel cell system; a refrigeration system, a selective catalytic reduction (SCR) system, a chemical feedstock production system, a system for production of synthetic fibers, a waste treatment system a water treatment system, and an agricultural applications.
An apparatus, comprising: a membrane; a membrane holder including an output, wherein the membrane holder is operable to hold the membrane and the membrane holder has three or more ports, and a permeate attachment coupled to the output of the membrane. The apparatus may further comprise a flow meter coupled to an output of a first pump, wherein the flow meter is disposed between the pump and the membrane holder.
Disclosed herein is a printer for manufacturing a construct for use as a prosthetic, the printer comprising a housing; a piston that is operative to reciprocate in the housing to extrude a volume of a hydrogel; and a stage comprising a porous screen and an inlet port disposed downstream of the housing; where the inlet port is operative to introduce air into the hydrogel; and where the porous screen is operative to reduce air bubble sizes in the hydrogel.
Toyota Motor Engineering & Manufacturing North America, Inc. (USA)
University of Connecticut (USA)
Inventor
Ukegawa, Hiroshi
Yang, Qian
Pattipati, Krishna
Joshi, Shailesh N.
Abstract
Systems, methods, and other embodiments described herein relate to predicting anomalous operation of a device and an associated remaining useful life (RUL). In one embodiment, a method includes acquiring usage information about operation of an electronic device. The method includes selecting at least one feature from the usage information according to an optimization. The method includes determining whether the least one feature indicates a presence of an anomaly in the operation of the electronic device according to an anomaly model. The method includes, responsive to detecting the anomaly, determining a remaining useful life (RUL) for the electronic device according to a RUL model. The method includes providing the RUL.
The present disclosure is directed to administration of native or recombinant human PRG4 (rhPRG4) as a means to treat sickle cell disease or other disorders in subjects in need of treatment thereof.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Disclosed herein is an analgesic composition comprising a therapeutically effective amount of at least one endocannabinoid, at least one cannabinoid, or a combination of the endocannabinoid and cannabinoid and at least one local anesthetic; where the endocannabinoid comprises one or more endocannabinoids, one or more analogues of the endocannabinoids, one or more pharmaceutically acceptable salts of the endocannabinoid, or a combination thereof; where the cannabinoid comprises one or more cannabinoids, one or more analogues of the cannabinoids, one or more pharmaceutically acceptable salts of the cannabinoid, or a combination thereof; where at least one of the endocannabinoid or the cannabinoid is in the form of particles.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
A biomaterial composition includes an uncrosslinked plant-based biomaterial functionalized with reactive groups that are operative to undergo a crosslinking reaction via free radical polymerization. A method for producing a biomaterial composition includes functionalizing an uncrosslinked plant-based biomaterial with reactive groups that are operative to undergo a crosslinking reaction via free radical polymerization to form a functionalized uncrosslinked plant-based biomaterial. Additional embodiments are provided.
Toyota Motor Engineering & Manufacturing North America, Inc. (USA)
University of Connecticut (USA)
Inventor
Ukegawa, Hiroshi
Viviano, Raymond P.
Joshi, Shailesh N.
Yang, Qian
Pattipati, Krishna
Abstract
Systems, methods, and other embodiments described herein relate to predicting anomalous operation of a device and an associated remaining useful life (RUL) estimation. In one embodiment, a method includes acquiring usage information about the operation of an electronic device. The method includes determining whether the usage information indicates the presence of an anomaly in the operation of the electronic device according to an anomaly model. The method includes, responsive to detecting the anomaly, determining a remaining useful life (RUL) for the electronic device according to a RUL model. The method includes providing the RUL estimate.
A novel recombinant subunit vaccine composition against avian Mycoplasma infection is described. The vaccine includes VlhA early phase antigens chosen based on their expression profile during the first 7 days of infection. The vaccine composition is shown to induce a protective immune response in chickens. Vaccine compositions and methods of making and using the vaccine compositions are described.
C07K 14/30 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
A system for printing biomaterials can include a mixer having a longitudinal axis. The mixer can define a flow channel that extends along the longitudinal axis. The mixer can have at least one inlet configured to receive a first printable biomaterial and a second printable biomaterial and an outlet spaced from the inlet along the longitudinal axis. One or more mixing elements positioned within the flow channel between the inlet(s) and the outlet of the mixer. The mixing element(s) can be configured to control a spatial distribution of the first and second printable biomaterials across and along the longitudinal axis.
A23P 20/20 - Making of laminated, multi-layered, stuffed or hollow foodstuffs, e.g. by wrapping in preformed edible dough sheets or in edible food containers
A23P 20/25 - Filling or stuffing cored food pieces, e.g. combined with coring or making cavities
B01F 25/4314 - Straight mixing tubes with baffles or obstructions that do not cause substantial pressure dropBaffles therefor with helical baffles
B29C 64/118 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using filamentary material being melted, e.g. fused deposition modelling [FDM]
The present disclosure is concerned with unilamellar liposomes and methods of making same. The disclosed unilamellar liposomes can be useful in, for example, delivering a cargo molecule (e.g., a nucleic acid) and also in inducing an immune response. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
59.
INHIBITORS OF CYTOCHROME P450 FAMILY 7 SUBFAMILY B MEMBER 1 (CYP7B1) FOR USE IN MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS
Disclosed are compounds for use in modulating a mobilization of hematopoietic stem and progenitor cells (HSPCs) or hematopoietic stem cells (HSCs) from the bone marrow to the peripheral blood in a subject; wherein the compound inhibits the activity of cytochrome P450 family 7 subfamily B member 1 (CYP7B1 inhibitor).
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A prosthetic device for repairing a damaged organ, includes a porous scaffold adapted for hosting a population of therapeutic cells, the porous scaffold having an outer surface and an inner surface separated by a thickness. A median pore size in the porous scaffold is less than a limiting median dimension for the population of therapeutic cells; and, a population of therapeutic cells is seeded upon the scaffold. The therapeutic cells include autologous cells in an amount of between about 10,000 cells to about 15,000 cells per square millimeter of surface area of the porous scaffold. Methods of imaging, fabrication and use are provided.
Disclosed are methods and compositions for treating or preventing a disease, a disorder, or symptom associated with picornaviruses in a subject including a therapeutically effective amount of a compound of Formula I, Formula II, or a pharmaceutically acceptable salt thereof, wherein X, Y, L, A, B, A1, A2, A3, R1, R2, R3, R4, R7, R8, R9, and R10 are as described herein.
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
41 - Education, entertainment, sporting and cultural services
Goods & Services
Entertainment and educational services in the nature of competitions in the field of entertainment, education, culture, sports, and other non-business and non-commercial fields
63.
Multiplexed, CRISPR-based Diagnostics of SARS-CoV-2 in Autonomous Microfluidic Device
Described herein is an autonomous, rapid, sensitive, point-of-care target nucleic acid detection system and method based on CRISPR/Cas system. The system and method allow naked eye visualization of multiple target nucleic acid molecules simultaneously in a biological sample in less than an hour. Use of the system and method for multiplex gene diagnosis of SARS-CoV-2 is exemplified.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
This disclosure relates to an engineered a novel synthetic artificial stem cell (SASC) system which mimics the paracrine effect of the stem cell secretome and provides tailorability of the composition for targeted tissue regeneration. This novel SASC system demonstrates the feasibility of developing a completely synthetic, tailorable stem cell secretome which reinforces the possibility of developing a new therapeutic strategy that provides better control over targeted tissue engineering applications. Disclosed herein are biodegradable polymeric microspheres that have been used to encapsulate secretome active agents. These microspheres mimic or have the potential to result in a greater therapeutic paracrine effect compared to stem cells, without the added risk of immunological response or the extra pro-inflammatory, antagonistic or inert factors/cytokines. The compositions may be personalized to any disease and/or individual, therefore, adding a much needed element to therapeutics.
The present invention relates to methods and compositions for treating an LRRK2-associate disorder or condition, e.g., Parkinson's Disease, methods for reducing or preventing neuronal cell death, and methods for reducing neurodegeneration and/or neuroinflammation, in a subject in need thereof, by an agent that decreases the expression of LRRK2, e.g., an agent that induces LRRK2 mRNA decay.
A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
66.
INTRACELLULAR CX3CL1 DOMAIN PEPTIDES AND USES THEREOF
Described is a polypeptide including the intracellular domain of CX3CL1 (CX3CL1- ICD), including an amino acid sequence that is at least 90% identical to SEQ ID NO: 1 and pharmaceutical compositions including the above-described polypeptide and a pharmaceutically acceptable excipient. Also included are nucleic acids expressing the polypeptides and expression cassettes and vectors comprising the nucleic acids. The polypeptides can be used in methods of treating a subject exhibiting a symptom of a neurodegenerative disease and/or diagnosed with a neurodegenerative disease and methods of treating a subject exhibiting a symptom of diabetes and/or diagnosed with diabetes comprising administering to the subject the pharmaceutical composition described herein.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
67.
THERMAL BARRIER COATINGS FOR INTERNAL COMBUSTION ENGINES
A thermal barrier coating for an internal combustion engine includes an insulating thermal spray coating, where a chosen material of the insulating thermal spray coating has a thermal conductivity lower than 2 W/mK in fully dense form and the chosen material includes a coefficient of thermal expansion within 5 ppm/K of a coefficient of thermal expansion of a material of a component of the internal combustion engine upon which the coating is placed.
Disclosed herein are uses of inhibitor of extracellular human metallothionein (MT) to treat a disorder selected from the group consisting of diabetes, pre-diabetes, impaired glucose tolerance, hepatitis, and/or inflammatory liver disease, and compositions containing extracellular human MT.
Described herein are apparati and methods for growing cells in a manner that mimics the native three-dimensional environment. Cell cultures grown in the apparatus can be screened for inhibition by specific chemotherapeutics or other drugs.
The disclosed hemicyanine dyes contain an amino-chromene moiety as an electron donor, facilitating a variety of optical properties and uses in sensing applications.
C07D 209/02 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
C09B 23/01 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain
A gut microbiome may be modulated in a patient in need thereof, by administering a composition comprising 3-O-acetyl-11-keto-b-boswellic acid (AKBA) or an extract of Boswellia serrata comprising from 30% to 90% AKBA to the patient; wherein the composition is administered at a dose sufficient to change the ratio between a first organism in the gut microbiome and a second organism in the gut microbiome, compared to a subject not treated with the composition. Modulation of the gut microbiome with AKBA may be used to treat allergic pulmonary inflammation in the patient. Modulation of the gut microbiome with AKBA may be used to maintain diversity and/or increase a percentage of Bifidobacterium pseudolongum in the gut microbiome of the patient. The composition may further comprise a lyophilized probiotic bacteria. The composition may be administered in combination with a second composition comprising a lyophilized probiotic bacteria.
Systems and methods for assessing the resilience of an infrastructural system. The system includes a computer program product stored on non-transitory machine-readable media. The media includes machine executable instructions for implementing a method for assessing the resilience of an infrastructural system. The method includes receiving, from an interface, scenario specific data regarding conditions for the infrastructural system; processing the scenario specific data to determine a vulnerability metric for a probability of failure for a component of the infrastructural system; determining, based on the vulnerability metric, an in-situ failure risk of the infrastructural system incorporating a complexity of environmental conditions; determining, based on the vulnerability metric, a recommended maintenance task for the component of the infrastructural system; and providing the in-situ failure risk of the infrastructural system and the recommended maintenance task for the component to the interface.
A process for removing contaminants from fuel includes providing a first container holding a quantity of cyclodextrin, introducing a fuel having an initial concentration of a contaminant into the container to cause the fuel to contact the quantity of cyclodextrin, wherein a portion of the contaminant associates with the cyclodextrin, and removing the fuel from the container, wherein the fuel removed from the container has a final concentration of the contaminant, and wherein the final concentration is less than the initial concentration. The fuel may be a biodiesel produced from low-quality feedstocks such as brown grease. The contaminant may be a sulfur contaminant and/or the contaminant may be a long hydrocarbon chain contaminant. The cyclodextrin may be a beta-cyclodextrin and/or a native cyclodextrin. The process may further include introducing water into the container while the fuel is in contact with the cyclodextrin.
A device and method for generating in-situ microneedles in a subject. The device includes a body, a microneedle coupled to the body, a reservoir coupled to the body, a first motor. The microneedle is positioned within a chamber at a distal end of the body. The reservoir includes a biomaterial fluid and is in fluid communication with the microneedle. The first motor is configured to activate the reservoir to expel the biomaterial fluid to the microneedle. The device also includes a temperature control assembly coupled to the reservoir and configured to set and maintain a temperature of the reservoir, a second motor coupled to the body and the microneedle, a microneedle size device coupled to the microneedle and configured to set a length of the microneedle extending from the chamber. Lastly, the device includes a user interface configured to receive input from a user to control the microneedle to penetrate the tissue to inject the biomaterial fluid into the tissue to generate an in-situ microneedle in the tissue.
A method for detecting a target molecule in a sample includes providing a capture species immobilized on a fixed surface; exposing the immobilized capture species to the sample to bind the target molecule; exposing the bound target molecule to a reporter complex to bind the reporter complex to the bound target molecule; and imaging the fixed surface to count the number of the reporter complexes or the number of an imageable product derived from each reporter complex. In an aspect, the signal of the bound target molecule can be amplified to provide an amplified signal that is then exposed to the reporter complex.
Compositions and methods for the treatment of a human subject in need of treatment for a neutrophil-related condition, in particular who has had a stroke or myocardial ischemia reperfusion injury, by administering to the subject a pharmaceutical composition including a compound of Formula 1,
Compositions and methods for the treatment of a human subject in need of treatment for a neutrophil-related condition, in particular who has had a stroke or myocardial ischemia reperfusion injury, by administering to the subject a pharmaceutical composition including a compound of Formula 1,
Compositions and methods for the treatment of a human subject in need of treatment for a neutrophil-related condition, in particular who has had a stroke or myocardial ischemia reperfusion injury, by administering to the subject a pharmaceutical composition including a compound of Formula 1,
wherein the substituents are as described herein, and in particular wherein the compound is 4,4-dimethyl-1-(3-nitrophenyl)-2-(1H-1,2,4-triazol-1-yl)-1-penten-3-one.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A powder mixing device, having: a stand; a frame mounted to the stand, the frame being rotatable around a first axis of rotation; and a mixing vessel mounted to the frame, the mixing vessel being rotatable around the first axis of rotation; wherein the mixing vessel comprises at least two components, a first segment and a second segment, wherein the first segment has a work function higher or lower than a work function of the second segment, and a work function of a powder to be mixed is within the work function of the first segment and the second segment.
A film comprises an elastomeric or soft polymer substrate that is capable of converting light to heat a second layer comprising a hydrophilic polymer and nanosheets of layered inorganic material dispersed in the hydrophilic polymer. The substrate can comprise a photothermal particle. The film can be used in a method by irradiating the film to cause wrinkles and optionally further exposing the film to moisture with optional drying.
B32B 27/08 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance of synthetic resin of a different kind
B32B 27/18 - Layered products essentially comprising synthetic resin characterised by the use of special additives
B32B 27/28 - Layered products essentially comprising synthetic resin comprising copolymers of synthetic resins not wholly covered by any one of the following subgroups
Disclosed herein are uses of inhibitor of extracellular human metallothionein (MT) to treat a disorder selected from the group consisting of diabetes, pre-diabetes, impaired glucose tolerance, hepatitis, and/or inflammatory liver disease, and compositions containing extracellular human MT.
A nasogastic device and method is provided, including a first flexible tube having a distal end configured to be threaded through the nose of a patient, down the esophagus and into the stomach for enteral feeding, a second flexible tube disposed adjacent to the first tube having a distal end proximate to the distal end of the first flexible tube, the distal end of the second tube configured to terminate inside the esophagus for delivery of liquids to the esophagus or for sampling of the local environment, an inflatable balloon configured around the first and second flexible tubes, the inflatable balloon disposed proximal to the distal end of the first and second flexible tubes, a third flexible tube in fluid communication with the balloon configured to inflate the inflatable balloon; and a fourth flexible tube having a distal end portion communicating with an exterior portion of the inflatable balloon, the fourth tube configured to transport suspensions or solutions of materials, such as therapeutic molecules into a space exterior to the inflatable balloon; and an elastomeric sleeve surround the inflatable balloon and around the fourth flexible tube which is used to control delivery of therapeutic suspensions of solutions of materials to the exterior of the device to the adjacent esophagheal tissue.
The disclosure provides materials and methods for detection of pathogens. In particular, the disclosure provides primers and compositions for detection of viral pathogens, such as SARS-CoV-2. In addition, the disclosure provides a warm-start digital CRISPR assay for detection of viral pathogens, including SARS-CoV-2.
An article for removing heat from a volume of space upon which it is disposed. The article includes a substrate upon which is disposed a super-hydrophilic dopant. The super- hydrophilic dopant is operative to absorb water from the substrate and to facilitate a conversion of water from a liquid phase to a vapor phase.
B32B 5/30 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by the presence of two or more layers which comprise fibres, filaments, granules, or powder, or are foamed or specifically porous one layer comprising granules or powder
B01J 20/02 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material
E04H 15/02 - Tents combined or specially associated with other devices
B32B 5/16 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by features of a layer formed of particles, e.g. chips, chopped fibres, powder
E04H 15/32 - Parts, components, construction details, accessories, interior equipment, specially adapted for tents, e.g. guy-line equipment, skirts, thresholds
84.
THERAPEUTICS TARGETING TRANSFORMING GROWTH FACTOR BETA FAMILY SIGNALING
Provided herein are methods of inhibiting type 1 receptor and/or type 2 receptor signaling in subjects, optionally subjects with diseases associated with myostatin, type 1 receptor, and/or type 2 receptor signaling, or muscle loss and/or bone deterioration. Also provided are compositions for inhibition of type 1 receptor and/or type 2 receptor signaling.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
Methods and systems of osteoarthritis treatment. One method includes providing a cartilage hydrogel, the cartilage hydrogel including piezoelectric nano-fibers of Poly-L-lactide (PLLA). The method also includes injecting the cartilage hydrogel into a cartilage defect. The method also includes applying an ultrasonic treatment to the cartilage defect. The method also includes, in response to applying the ultrasonic treatment to the cartilage defect, converting a mechanical impact of the ultrasonic treatment into an electrical charge from the piezoelectric nano-fibers of PLLA and providing, in response to the electrical charge from the piezoelectric nano-fibers of PLLA, chondrogenesis differentiation for cartilage regeneration for the cartilage defect.
Disclosed herein are systems and methods for effectively predicting cardiovascular disease risk in people with normal lipid profiles and/or in people undergoing lipid management therapy. Genetic information obtained from a patient may be characterized. A logistic regression model may be applied to the characterized genetic information to estimate a probability of a cardiovascular event by the patient.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16B 25/00 - ICT specially adapted for hybridisationICT specially adapted for gene or protein expression
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
87.
COMPOSITIONS AND METHODS FOR PHARMACOLOGIC TREATMENT OF STROKE AND MYOCARDIAL ISCHEMIA REPERFUSION INJURY
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Liang, Bruce T.
Verma, Rajkumar
Jacobson, Kenneth A.
Toti, Kiran S.
Abstract
Compositions and methods for the treatment of a human subject who has had a stroke or myocardial ischemia reperfusion injury, by administering to the subject a pharmaceutical composition including a compound of Formula (I) and/or of Formula (5) or a pharmaceutically acceptable salt and/or formulation thereof. The pharmaceutical composition can be administered in the acute phase of stroke, optionally in combination with a thrombolytic therapeutic or a procedure on the subject involving a clot-removal device.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/5395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
An apparatus for generating a droplet of a liquid metal material in a metal additive manufacturing process includes a nozzle configured to eject the droplet of the liquid metal material, the nozzle including a conductive solid. The apparatus also includes a voltage source configured to apply voltage between the conductive solid and the liquid metal material to modify a contact angle between an inner wall of the nozzle and the liquid metal material within the nozzle. The apparatus also includes a controller configured to modify the voltage from the voltage source to modify the contact angle and generate the droplet of the liquid metal material.
Provided herein are polycannabinoid compositions, uses thereof and methods of manufacturing the same. Polycannabinoid compositions described include polymers of a single cannabinoid type or polymers with a variety of cannabinoids. Such compositions are further described as optionally present as a mixture of longer and short polymers having differential functions as a result of size. Compositions are optionally described for combination with carriers. A variety of conditions are described for treatment with such compositions, including cancer, anxiety, and sleep disturbance.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Described herein are compositions and methods for stabilizing RNA and protein antigens for long-term storage and use in transdermal microneedle patches, methods for filling microneedles, and methods of use. A stabilized RNA vaccine composition comprises: a complex of RNA with one or more cationic polymers; and one or more cationic lipid entities. A method for stabilizing RNA comprises: forming a complex comprising the RNA with one or more cationic polymers; mixing the complex with one or more cationic lipid entities comprising liposomes or lipid nanoparticles to form a lipid mixture; and drying the lipid mixture under vacuum. The compositions and methods may be employed in the preparation of vaccine medicaments.
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
A61K 9/00 - Medicinal preparations characterised by special physical form
Disclosed herein are self-assembled nanomaterials that include a Janus base nanotube having a biologically active molecule noncovalently adhered thereto, wherein the biologically active molecule is an extracellular matrix (ECM) molecule, a bioactive molecule, or a combination thereof.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
B82B 1/00 - Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
92.
FORMULATIONS FOR ADMINISTERING LAAM, norLAAM AND dinorLAAM AND METHODS OF THEIR USE TO TREAT OPIOID USE DISORDER
Rapid-release formulations for administering Levo-alpha-acetylmethadol (LAAM), norLAAM and dinorLAMM and, optionally, magnesium, are provided. The formulations include solid i) core-shell oral dosage forms delivered in capsules or tablets, and ii) electrospun nano/microfiber buccal film dosage forms. Methods of the use of the formulations to treat opioid use disorder (OUD) and pain are also provided.
Methods, systems, non-transitory computer-readable media, and apparatuses are described for predicting a health condition of a subject. An apparatus may be configured to receive a physiological signal associated with the subject. The physiological signal may include artifacts. A modified physiological signal may be generated based on an application of a machine learning model to the physiological signal. The modified physiological signal may include the physiological signal with a reduction of the artifacts. A physiological measurement may be determined based on the modified physiological signal. The health condition may be determined based on a change in the physiological measurement satisfying a threshold. The apparatus may cause an output of an indication associated with the health condition.
A therapeutic bandage includes a bandage matrix and an array of microneedles extending from the bandage matrix. Each of the microneedles includes a first layer that encapsulates a first immunomodulatory compound and a second layer that encapsulates a second immunomodulatory compound. The array of microneedles is configured to guide foreign agents affected by the first immunomodulatory compound, the second immunomodulatory compound, or the first and second immunomodulatory compounds from one or more skin layers of a user to the bandage matrix such that the bandage matrix absorbs and captures the foreign agents.
A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
A61L 15/22 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
A personalized method of treating a cancer patient with a tumor utilizing a computing system having a processing system and a memory system storing instructions that are executed by the processing system, the method having the computing system performing steps of: performing parameter estimation to determine physiological parameters π of the tumor, including vascular hydraulic conductivity and interstitial hydraulic conductivity; determining whether the selected tumor transport model is valid or invalid by solving for physiological parameters π, and upon determining that the selected tumor transport model is valid, the method includes determining a treatment; and according to the method, the treatment is applied to a cancer patient.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
A novel peptide nucleic acid (PNA) oligomer capable of forming a PNA/RNA/PNA triplex when binding to its target RNA is described. An anti-micro RNA (miRNA) capable of binding miR-155 was designed based on the novel PNA oligomer and was shown to significantly decrease miR-155 expression in vitro in lymphoma cell lines. In vivo testing in xenograft mouse models resulted in reduced miR-155 expression followed by reduced tumor growth. Methods of making and using the novel PNA oligomer for targeting other coding and noncoding RNAs are described.
C-MycC-Myc oncogene was capable of binding the target DNA and effectively inhibit the transcription of the gene both in vitro as well as in vivo without causing any toxicity. Methods of making and using the novel PNA oligomer for targeting other genomic DNA are described.
A genetic sequence-carbohydrate conjugate is disclosed, having a formula (I): wherein GS is a genetic sequence, preferably a peptide nucleic acid or an oligonucleotide such as an mRNA sequence, an siRNA sequence, or a DNA sequence, optionally wherein each genetic sequence is natural or modified, and the variables are as described herein. Also disclosed are uses for the genetic sequence-carbohydrate conjugates, including as RNA therapeutics targeting the liver and kidneys of a mammal, including a human.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61K 47/56 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
